DexCom, Inc. $DXCM Shares Acquired by Farther Finance Advisors LLC

Farther Finance Advisors LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,680 shares of the medical device company’s stock after purchasing an additional 580 shares during the period. Farther Finance Advisors LLC’s holdings in DexCom were worth $321,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Golden State Wealth Management LLC boosted its holdings in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom during the 1st quarter valued at approximately $27,000. Anderson Financial Strategies LLC purchased a new stake in shares of DexCom during the 1st quarter valued at approximately $37,000. Alpine Bank Wealth Management purchased a new stake in shares of DexCom during the 1st quarter valued at approximately $40,000. Finally, Private Trust Co. NA raised its position in shares of DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after buying an additional 335 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 1.0%

Shares of NASDAQ DXCM opened at $66.46 on Tuesday. The firm has a market cap of $26.06 billion, a price-to-earnings ratio of 46.15, a PEG ratio of 1.41 and a beta of 1.48. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The business’s 50 day moving average is $77.92 and its two-hundred day moving average is $78.10.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently commented on DXCM shares. Piper Sandler lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the company an “overweight” rating in a research report on Thursday, July 31st. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Robert W. Baird reduced their price target on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a research report on Friday. UBS Group lifted their price target on shares of DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Finally, Mizuho lifted their price target on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.11.

Insider Buying and Selling at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the business’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares in the company, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.